Most U.S. insurance carriers, including Medicare, Aetna, United Healthcare, and CIGNA, cover the Oncotype DX test for early-stage, node-negative, estrogen receptor-positive, invasive breast cancer patients, but some carriers have yet to establish coverage policies for DCIS (non-invasive) and node-positive breast cancers.
The Genomic Access Program (GAP) can help you verify whether your insurance covers the test and, if so, help you obtain reimbursement. GAP is designed for women covered by a U.S. insurance company. Please note that you may be financially responsible for some or all of the cost associated with the test. If your insurance carrier does not cover some or all of the cost of the test, you can request GAP's assistance in setting up a payment plan. To learn more about GAP, please call Genomic Health Customer Service at 855.5000.ASK (855-500-0275).